
Scopoletin and umbelliferone from Cortex Mori as protective agents in high glucose-induced mesangial cell as in vitro model of diabetic glomerulosclerosis
Author(s) -
Yuan Liang,
Xianlu Zeng,
Jialiang Guo,
Hui Liu,
Bin He,
Renyu Lai,
Quan Zhu,
ZongPing Zheng
Publication year - 2021
Publication title -
chinese journal of physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.396
H-Index - 31
eISSN - 2666-0059
pISSN - 0304-4920
DOI - 10.4103/cjp.cjp_9_21
Subject(s) - ctgf , glomerulosclerosis , scopoletin , fibronectin , mesangial cell , extracellular matrix , chemistry , growth factor , fibrosis , transforming growth factor , endocrinology , renal hypertrophy , medicine , microbiology and biotechnology , umbelliferone , kidney , biology , biochemistry , diabetic nephropathy , pathology , coumarin , receptor , alternative medicine , proteinuria , organic chemistry
Two known coumarins, scopoletin (SP) and umbelliferone (UB), were isolated from Cortex Mori (CM). Their structures were elucidated by various spectroscopic analyses. Then, their effects on rat glomerular mesangial cells (RGMCs, HBZY-1) proliferation, hypertrophy, extracellular matrix (ECM) proliferation, expression of fibronectin, transforming growth factor-beta (TGF-β), and connective tissue growth factor (CTGF) induced by high glucose were studied in vitro model of diabetic glomerulosclerosis. The results show that, CM, SP, and UB can inhibit the RGMCs proliferation to attenuate the ECM proliferation and cell hypertrophy, reduced the accumulation of ECM protein fibronectin, and lowered the expression of the key fibrosis factor TGF-β and CTGF to inhibit the kidney fibrosis and thereby improved diabetic glomerulosclerosis. The two coumarins show great potentialities on treating diabetic glomerulosclerosis, but the animal experiment and mechanism is strongly needed for further proof.